Updated on 23 July 2012
For all other approved indications the CHMP considered that the benefit-risk balance remains positive, but recommended that calcitonin treatment should be given for the shortest possible time. For the treatment of patients with Paget's disease, the CHMP also recommended to limit the use of calcitonin to a second-line indication in patients who do not respond to alternative treatments or for whom such treatments are not suitable. Treatment in this condition should normally be limited to 3 months; however, it may be extended to 6 months in exceptional circumstances, and intermittently repeated if it is considered that the potential benefits outweigh the risks.
The CHMP's opinion is being forwarded to the European Commission for the adoption of a decision.